Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism
Key facts
- Who runs it
- Copenhagen University Hospital, Rigshospitalet
- Where
- Denmark4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 210 people, planned
- Started
- 6 Jun 2019
- Ended
- 30 Nov 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Alteplase 20 Mg Powder for Solution for Injection Vial
- Ultrasound assisted Thrombolysis
- Record updated
- 15 November 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age ≥ 18 years
- Informed consent for trial participation
- Intermediate high-risk PE according to ESC criteria
- Thrombus visible in main, lobar or segmental pulmonary arteries on CT angiography
- 14 days of symptoms or less
Who cannot take part
- Ongoing oral anticoagulation therapy (heparins, aspirin, antiplatelet therapy and NOAC allowed)
- Absolute contraindications for thrombolysis; Hemorrhagic stroke or stroke of unknown origin at any time; Ischemic stroke in the preceding 6 months; Central nervous system damage or neoplasms; Recent major trauma/surgery/head injury in the preceding 3 weeks; Gastrointestinal bleeding within the last month; Known bleeding risk
- Altered mental state (GCS < 14)
- No qualifying CT angiography performed (> 24 hour since CT angiography)
- Females of child bearing potential, unless negative HCG test is present
- Thrombolysis for PE within 14 days of randomization
- Thrombus passing through patent Foramen Ovale (risk of paradoxical embolism)
- Comorbidity making 6 months survival unlikely
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Open label clinical randomized trial comparing three strategies for managing acute intermediate-high risk pulmonary embolism
The 3 groups in the trial
- USAT + low dose thrombolysisExisting treatment, for comparison
UltraSound Assisted Thrombolysis (USAT) with low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus unfractionated heparin (UFH) or low molecular weight heparin (LMWH) within 12 hours of randomization
Treatment: Alteplase 20 Mg Powder for Solution for Injection Vial and Ultrasound assisted Thrombolysis
- Low dose thrombolysisExisting treatment, for comparison
Intravenous low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus UFH or low molecular weight heparin (LMWH).
Treatment: Alteplase 20 Mg Powder for Solution for Injection Vial
- Heparin aloneNo study treatment, for comparison
UFH or low molecular weight heparin (LMWH) only (with option for conventional thrombolysis according to local protocols for hemodynamic deterioration)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Publications
- Randomized trial of low-dose, ultrasound-assisted thrombolysis or heparin for pulmonary embolism.Cardiovascular research, 2026
- A randomized trial of low-dose thrombolysis, ultrasound-assisted thrombolysis, or heparin for intermediate-high risk pulmonary embolism-the STRATIFY trial: design and statistical analysis plan.Trials, 2024
- Record updated
- 15 November 2024